Abstract
Introduction: Prostate cancer is the second-leading cause of cancer death in men. Sinularin is a soft coralsderived natural compound that has anticancer activity in many cancer cells. However, the pharmacological action of sinularin in prostate cancer is unclear.
Aim: The aim of the study is to examine the anticancer effects of sinularin in prostate cancer cells.
Methods: We explored the anticancer effects of sinularin on the prostate cancer cell lines, PC3, DU145, and LNCaP, by MTT, Transwell assay, wound healing, flow cytometry, and western blotting.
Results: Sinularin inhibited the cell viability and colony formation of these cancer cells. Furthermore, sinularin inhibited testosterone-induced cell growth in LNCaP cells by downregulating the protein expression levels of androgen receptor (AR), type Ⅱ 5α-reductase, and prostate-specific antigen (PSA). Sinularin significantly attenuated the invasion and migration ability of PC3 and DU145 cells, with or without TGF-β1 treatment. Sinularin inhibited epithelialmesenchymal transition (EMT) in DU145 cells after 48 h of treatment by regulating the protein expression levels of Ecadherin, N-cadherin, and vimentin. Sinularin induced apoptosis, autophagy, and ferroptosis by regulating the protein expression levels of Beclin-1, LC3B, NRF2, GPX4, PARP, caspase-3, caspase-7, caspase-9, cleaved-PARP, Bcl-2, and Bax. Moreover, intracellular reactive oxygen species (ROS) were increased but glutathione was decreased after sinularin treatment in PC3, DU145 and LNCaP cells.
Conclusion: Sinularin regulated the androgen receptor signaling pathway and triggered apoptosis, autophagy, and ferroptosis in prostate cancer cells. In conclusion, the results indicated that sinularin may be a candidate agent for human prostate cancer and need further study for being applied to human.
Graphical Abstract
[http://dx.doi.org/10.1007/978-3-319-95693-0_1] [PMID: 30229546]
[http://dx.doi.org/10.1111/iju.13512] [PMID: 29266472]
[http://dx.doi.org/10.1053/j.semnuclmed.2016.07.002] [PMID: 27825428]
[http://dx.doi.org/10.3390/ijms19092729] [PMID: 30213077]
[http://dx.doi.org/10.14715/cmb/2020.66.4.6] [PMID: 32583788]
[http://dx.doi.org/10.3390/ijms22083946] [PMID: 33920454]
[http://dx.doi.org/10.7150/jca.31232] [PMID: 31602264]
[http://dx.doi.org/10.3390/molecules23040849] [PMID: 29642488]
[http://dx.doi.org/10.1002/tox.22425] [PMID: 28548367]
[http://dx.doi.org/10.3390/md14080142] [PMID: 27472346]
[http://dx.doi.org/10.1186/s12906-017-1583-9] [PMID: 28103869]
[http://dx.doi.org/10.3390/antiox11081433] [PMID: 35892635]
[http://dx.doi.org/10.1038/s41580-018-0080-4] [PMID: 30459476]
[http://dx.doi.org/10.3390/molecules24061131] [PMID: 30901941]
[http://dx.doi.org/10.3892/or.2020.7595] [PMID: 32627027]
[http://dx.doi.org/10.21873/anticanres.14311] [PMID: 32487624]
[http://dx.doi.org/10.1002/cncr.31335] [PMID: 29671878]
[http://dx.doi.org/10.1016/j.cell.2018.09.048] [PMID: 30633901]
[http://dx.doi.org/10.1002/cbin.11137] [PMID: 30958602]
[http://dx.doi.org/10.1016/bs.irn.2017.02.012] [PMID: 28807161]
[http://dx.doi.org/10.1007/s00280-018-3707-4] [PMID: 30353226]
[http://dx.doi.org/10.1016/j.freeradbiomed.2018.09.043] [PMID: 30268886]
[http://dx.doi.org/10.1016/j.phrs.2021.105580] [PMID: 33781874]
[http://dx.doi.org/10.4161/auto.22397] [PMID: 23075929]
[http://dx.doi.org/10.3390/cells9122653] [PMID: 33321757]
[http://dx.doi.org/10.3390/md18100487] [PMID: 32992719]
[http://dx.doi.org/10.2174/1875533XMTA02OTAxz] [PMID: 32107991]
[http://dx.doi.org/10.1002/path.5680] [PMID: 33834494]
[http://dx.doi.org/10.1016/bs.apcsb.2021.01.003] [PMID: 33931145]
[http://dx.doi.org/10.4143/crt.2016.572] [PMID: 28494534]
[http://dx.doi.org/10.3389/fphar.2020.01061] [PMID: 32774303]